KR102663392B1 - Composition for preventing or improving oral diseases comprising an extract of saussurea neoserrata - Google Patents

Abstract

The present invention relates to a composition for preventing or improving oral diseases. In the case where it contains the extract of mountain odor as an active ingredient, there is no concern about side effects due to long-term administration due to the use of natural products, and it is used in the gingival tissue in a periodontal disease induction model. It shows activity in preventing or improving periodontal disease through reduction of IL-1β, TNF-α and MDA content, activity in reducing osteoclast formation, activity in increasing periodontal bone mass, and reduction in the total number of aerobic bacteria in the oral buccal area in a periodontal disease-induced model, while also increasing the amount of saliva secretion. It can improve dry mouth by improving dry mouth, showing activity in preventing or improving oral diseases including periodontal disease and dry mouth.

Description

Composition for preventing or improving oral diseases comprising extract of mountain odor {COMPOSITION FOR PREVENTING OR IMPROVING ORAL DISEASES COMPRISING AN EXTRACT OF SAUSSUREA NEOSERRATA}

The present invention relates to a composition for preventing or improving oral diseases. More specifically, it relates to a composition that exhibits preventive or ameliorating activity for oral diseases, including dry mouth and periodontal disease, by containing an extract of mountain odor as an active ingredient.

Healthy teeth are such an important factor in determining the quality of life that they are called one of the five blessings. Among oral diseases, dental caries (cavities) and periodontal disease (periodontal disease) are diseases with a high incidence worldwide and are associated with various clinical symptoms such as pain, impaired chewing function, destruction of periodontal tissue, bad breath, and sensitive teeth. It is known to be the main factor causing tooth loss, and the causative factors of oral diseases are increasing due to changes in eating habits.

It is known that approximately 600 to 800 types of microorganisms exist in the human oral cavity, and these microorganisms are controlled by enzymes such as lysozyme secreted by saliva. However, an oral environment rich in nutrients and moisture is a good condition for the growth of microorganisms, and the tongue and dental plaque provide an excellent habitat for microorganisms. Some of these microorganisms are opportunistic pathogens and cause diseases such as dental caries, periodontal disease, and dentinal hypersensitivity, as well as bad breath.

There are antibacterial agents as a way to suppress the growth of oral pathogens that live in plaque and cause dental caries, periodontal disease, bad breath, and sensitive teeth. Various types of antibacterial agents, including antibiotics that have sterilizing and bacteriostatic effects on oral pathogens, are used to treat cavities, It has been developed as a treatment and suppressant for periodontal disease, dental pulp, and periapical infections.

However, antibiotics have the disadvantage of being difficult to use long-term and being used only as a treatment because they can cause systemic side effects on our body and the emergence of resistant bacteria in the oral cavity and bacterial superinfection. In addition, antibacterial agents used in mouthwashes include Sangquinarine, Listerine, Peroxide, and Chlorhexidine, but the effectiveness of Sangquinarine against bacteria in the oral cavity is unclear. Not only is the treatment effect for periodontal disease more unclear, but it is also more expensive. Listerine has alcohol as its main ingredient and has a slight bacteriostatic effect, but it only has a temporary effect in the oral cavity and may be harmful to tissues when used for a long period of time. There are disadvantages that may appear.

In addition, pyroxide, which has recently been added for whitening effect, is toxic to bacteria, but is also toxic to human tissue, which not only poses a safety problem, but sometimes resistant bacteria to pyroxide appear in bacteria. In addition, chlorhexidine is known to be the best among the agents known to date as a preventive and therapeutic agent for periodontal disease in addition to inhibiting plaque formation. However, it causes tissue irritation, discoloration and degeneration of tissues, and has side effects such as a particularly strong irritating taste and strong odor. In addition to the problems it presents, it has the disadvantage of not being able to be used for long periods of time for treatment or especially prevention purposes, such as it can cause bacterial hyperplasia and is carcinogenic, so its use is restricted to pregnant women.

On the other hand, xerostomia is a disease in which the oral mucosa dries out due to a decrease in saliva secretion due to various causes. It mainly complains of abnormalities in chewing and speech functions, causes severe bad breath and tooth decay, and depending on the degree, You may experience severe pain due to a burning sensation in the oral mucosa or ulcers in the oral mucosa.

Saliva plays an important role in maintaining oral environment and oral function. In other words, saliva has two functions: food intake and oral environment maintenance. Regarding the food intake function of saliva, saliva maintains the sense of taste through digestion, such as the formation of food lumps and the action of digestive enzymes, or the solubilization of taste irritants or the secretion of gastin (carbonate dehydrogenase). It shows action. In terms of the oral environment maintenance function, saliva exhibits a self-purifying effect on teeth and mucous membranes, a recalcification effect of teeth, an antibacterial effect, an immune effect, an effect to promote tissue repair by growth factors, etc., and an anti-inflammatory effect.

Recently, the number of patients complaining of decreased saliva secretion caused by various factors is increasing. Therefore, social demand for his treatment is increasing. Reduced saliva secretion is associated with other diseases such as abnormalities in the salivary glands themselves caused by radiation therapy or parotitis, metabolic diseases (e.g., Basedow's disease, diabetes, etc.), or collagen diseases, and reduced saliva secretion is also caused by stress. It can also be caused by factors or side effects of various medications. With the recent aging of the population, the function of the salivary glands deteriorates due to aging, and the number of patients complaining of decreased salivary secretion as a result of various drug therapies for various complex diseases that occur in elderly people is expected to increase in the future. It is becoming.

Decreased salivary secretion is a result of dry mouth, causing the tongue to turn red and sometimes crack. Patients with decreased salivary secretion complain of pain when eating and difficulty chewing or swallowing. In addition, decreased saliva secretion is known to cause an uncomfortable feeling in the oral cavity, taste and pronunciation disorders, denture instability, tooth decay, onset of periodontitis, stomatitis, pneumonia, and digestive dysfunction.

Topical application of artificial saliva is used as a treatment for decreased salivary secretion, but its effect is temporary and limited. As salivary secretion stimulants, anethole trithion, known as a muscarinic receptor agonist, and cevimeline hydrochloride are used, but their effects are unstable and there is a possibility of digestive side effects such as nausea, vomiting, loss of appetite, and abdominal discomfort. There are some downsides. In this situation, the development of a new therapeutic agent for the treatment of decreased saliva secretion is desired.

Accordingly, the present invention was completed in order to provide a composition containing the extract of sorghum as an active ingredient to improve oral diseases while minimizing side effects.

KR 10-2288920 B1 KR 10-2251534 B1

An object of the present invention relates to a composition for preventing or improving oral diseases containing extract of mountain snail as an active ingredient.

Another object of the present invention is to provide a food composition or quasi-drug composition that has excellent effects in preventing or ameliorating oral diseases, including an extract of Sangolchwi extract as an active ingredient.

Another object of the present invention is to provide a pharmaceutical composition that is excellent in the prevention or treatment of oral diseases and contains an extract of sorghum as an active ingredient.

In order to achieve the above object, a composition for preventing or improving oral diseases according to an embodiment of the present invention contains an extract of mountain bone odor as an active ingredient.

The oral disease is selected from the group consisting of periodontal disease, dry mouth, dental caries, toothache, dry teeth, and bad breath.

The extract is extracted using an extraction solvent selected from the group consisting of water, C ₁ to C ₆ lower alcohols, and mixtures thereof.

A food composition for preventing or improving oral diseases according to another embodiment of the present invention includes the composition.

A quasi-drug composition for preventing or improving oral diseases according to another embodiment of the present invention includes the composition.

The quasi-drug composition is one or more formulations selected from the group consisting of toothpaste, mouthwash, mouthwash, gum, candy, oral spray, oral ointment, oral varnish, oral rinse, and gum massage cream.

A pharmaceutical composition for preventing or treating oral diseases according to another embodiment of the present invention includes the composition.

Hereinafter, the present invention will be described in more detail.

The term 'extract' used in this specification has the meaning commonly used in the art as a crude extract, as described above, but in a broad sense also includes fractions obtained by additional fractionation of the extract.

In other words, natural extracts include not only those obtained using extraction solvents, but also those obtained by additionally applying a purification process. For example, fractions obtained by passing the extract through an ultrafiltration membrane with a certain molecular weight cut-off value, separation by various chromatographs (designed for separation according to size, charge, hydrophobicity, or affinity), etc. Fractions obtained through purification methods are also included in the natural extract of the present invention.

The natural extract used in the present invention can be prepared in powder form by additional processes such as reduced pressure distillation and freeze drying or spray drying.

As used herein, the term 'including as an active ingredient' means containing a sufficient amount to achieve the efficacy or activity of the natural extract below.

A composition for preventing or improving oral diseases according to an embodiment of the present invention contains an extract of mountain snail root as an active ingredient.

The saussurea neoserrata nakai grows deep in the mountains and has a height of 50 to 110 cm. The stem stands upright and sometimes produces branches from the upper part. The base of the leaf flows into the stem and becomes the stem's wings. The leaves on the roots and the leaves on the bottom fall when flowers bloom, and the leaves on the stems are alternate, lanceolate or oval-shaped, and are 12 to 15 cm long. The end is sharp and the bottom is narrow. It gets smaller toward the top, has curly hairs on the back, and has sharp sawtooth edges. Also, the purple flowers bloom in August or September. Head flowers grow in corymbs at the ends of branches and main stems, and the flowers are 8 to 10 mm in diameter. The involucre is barrel-shaped, 8 to 9 mm long and 4 to 5 mm in diameter. The bract pieces are arranged in four rows, have purple edges and have white hairs like spider webs. The fruit is an achene, about 5 mm long, and has black-brown lines. The hairs have two rows and are brown. Young shoots are edible. It is a species endemic to Korea and is distributed in the northern region.

The present invention can exhibit prevention or improvement activity of oral diseases by including the extract of mountain odor as an active ingredient.

The oral disease is selected from the group consisting of periodontal disease, dry mouth, dental caries, toothache, dry teeth, and bad breath.

The oral diseases refer to various diseases that occur in the oral region, and the oral region refers to the space in the mouth connected to the pharynx from the front lips to the back oral cavity. In the present invention, the oral disease is a concept that includes all diseases that occur in the oral cavity regardless of the condition, and in the present invention, it is defined as selected from the group consisting of periodontal disease, dry mouth, dental caries, toothache, sensitive teeth, and bad breath. did.

The periodontal disease (periodontal disease) is a disease in which inflammation occurs in the gingiva, periodontal ligament, and bone tissue supporting the teeth. It is also commonly referred to as gum disease, and is divided into gingivitis and periodontitis depending on the degree of the disease. It is a relatively mild and fast-recoverable form of periodontal disease. When it is limited to the gums, or soft tissue, it is called gingivitis. When this inflammation progresses to the area around the gums and gum bones, it is called periodontitis. There is a V-shaped gap between the gingiva (gum) and the tooth. When oral pathogens attack the area below the gum line in this groove (sulcus), they release lipopolysaccharide (LPS), an inflammatory irritant, which causes Inflammation occurs, including swelling and bleeding of the gums, which damages the periodontal ligament and adjacent tissues. As periodontitis progresses, the periodontal ligament and even the alveolar bone are damaged, ultimately leading to tooth loss. Malnutrition such as protein and vitamins, hormonal disorders such as pregnancy or diabetes, smoking, and acquired immunodeficiency syndrome (AIDS) can worsen the disease. Additionally, other causes of periodontal disease include plaque and tartar. The periodontal disease of the present invention includes all causative bacteria that cause periodontal disease, regardless of the type, but specifically, Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, and Tane. It may be one or more species selected from the group consisting of Tannerella forsythia, Treponema denticola, and Fusobacterium nucleatum, and more specifically, Porphyromonas ginji It could be Balis.

The Porphyromonas gingivalis is a type of Bacteroide flexible bacteria, a Gram-negative bacterium, and an anaerobic bacterium. The Porphyromonas gingivalis is found in the oral cavity where periodontal disease occurs, and is also found in the upper gastrointestinal tract, respiratory tract, and colon. In patients with chronic periodontal disease, collagen is decomposed by the collagenase enzyme of the bacteria, and the bacteria can invade gingival fibroblasts and survive even under high concentrations of antibiotics. Additionally, the bacteria can invade gingival epithelial cells and survive for a long time.

The dry mouth (xerostomia) is a disease in which the oral mucosa dries out due to a decrease in saliva secretion. It can be caused by systemic causes such as Sjögren's syndrome, anemia, diabetes, nutrient deficiency, aging, drug use, nervous system disease, etc. It is a disease that mainly complains of abnormalities in chewing and speech functions, causes severe bad breath and tooth decay, and, depending on the severity, causes severe pain due to a burning sensation in the oral mucosa or ulcers in the oral mucosa.

The dental caries (dental cavities) is an infectious disease caused by bacteria living on the surface of the teeth, and is also called cavities, and shows symptoms of erosion and loss of the hard tissues of the teeth. Specifically, the milky-white, translucent, hard substance that covers the surface of the head of the tooth and protects the dentin of the tooth is called tooth enamel or enamel. It is damaged by acids produced when sugar, starch, etc. are broken down by oral pathogens living in the mouth. This means that the enamel of the teeth is damaged, resulting in cavities. The main cause of dental caries is dental plaque, which is a bacterial film formed on the surface of the teeth. Saliva forms a thin, sticky film on the teeth, and Streptococcus sobry, a type of streptococcus, forms on it. Dental plaque is created when oral microorganisms such as Streptococcus sobrinus and Streptococcus mutans attach and form a biofilm, which is further formed by Fusobacterium. It becomes thicker.

Toothache refers to pain in the tooth when eating sweet food, or very cold or hot food, and generally includes not only pain in the tooth itself, but also pain in the periodontal tissue that supports the tooth to the jawbone. do. It usually causes pain when chewing, gums swell, and foul-smelling discharge comes out. Toothache causes slightly different pain depending on the cause of the disease. Specifically, the pain caused by dental caries is painless in the beginning, but gradually progresses and pain appears when the nerve inside the tooth is deeply rotted, and in the case of an impacted tooth, inflammation of the tissues around the tooth causes pain. Pain is caused, and when a tooth is broken or cracked, when it touches cold food or bites hard, the tooth splits and irritates the nerve, causing pain. In the case of pulpitis, in the early stages, pain is felt when cold food touches it, and in more advanced cases, pain is felt when hot food is touched. As the inflammation progresses and the pulp tissue dies, there is no response to cold or hot things, and the periapex (end of the tooth root) Pain occurs due to inflammation.

The syrin refers to teeth with hypersensitive dentine, and the syrin symptoms refer to dentine hyperesthesia. Sensitivity is a symptom in which the exposed dentin of teeth feels sensitive when it comes in contact with cold air or irritating food, and 60 to 98% of adults with periodontal disease show the symptom. Symptoms of sensitive teeth occur when teeth are dented in the gum area due to incorrect tooth brushing habits, excessive bite force, dissolution by acid, poor oral hygiene, after periodontal treatment, after receiving restorative treatment, or when teeth are dissolved due to acidification. It may appear. The fundamental cause of this symptom is that many tubules present in the dentin of the tooth are exposed to the outside. Due to this exposure, all stimulation is transmitted to the nerves within the pulp, making the patient react more sensitively to the same stimulation than usual, which can cause pain. there is. Symptoms of sensitive teeth can range from mild symptoms to intense and persistent pain. Due to the nature of teeth, they do not regenerate, so taking painkillers or anti-inflammatory drugs is not a fundamental solution to the sensitive condition. Sensitivity may appear throughout the teeth, or may be limited to specific areas such as the upper or lower jaw, or the right or left side. The most affected area varies depending on the cause, but it is mainly the canines and premolars, and the most painful area in more than 90% of cases is the cervical region, which is the border between the gums and teeth.

The bad breath is an odor originating from the oral cavity and adjacent organs, and 85 to 90% of bad breath originates from the oral cavity, especially from the back of the tongue. The main components of bad breath are volatile sulfur compounds, and 90% of the total amount of volatile sulfur compounds are hydrogen sulfide made from cysteine, and methyl mercaptan and dimethyl sulfide made from methionine. These ingredients are mainly produced by protein enzymes secreted by anaerobic bacteria, and the back of the tongue is their most important habitat. This area is not cleaned well by saliva and has many small depressions, making it a place where bacteria continue to live. The production of volatile sulfur compounds by anaerobic bacteria is the most important cause of bad breath, but it can also be caused by other oral diseases such as dental caries, periodontitis, and dry mouth. Many types of anaerobic bacteria are involved in causing bad breath, and a non-limiting example of the bacteria causing bad breath is Porphyromonas gingivalis, which secretes many types and large amounts of enzymes.

Accordingly, the composition containing the mountain bone odor extract of the present invention as an active ingredient can exhibit an effect of preventing or improving oral diseases selected from the group consisting of periodontal disease, dry mouth, dental caries, toothache, dry teeth, and bad breath.

Preferably, it may exhibit a preventive or improvement effect on periodontal disease and dry mouth.

The composition for preventing or improving oral diseases containing the extract of mountain odor of the present invention as an active ingredient may further include extract of alpine insufficiency body, Cacalia extract, and fine leaf body extract.

Coelopleurum saxatile DRUDE. is a perennial herb of the Umbrella family. The roots are thick and deep, the stems are upright, have ridges, branch from the bottom, often have beautiful hairs at the nodes, and are 25 to 40 cm tall. am. The leaves are 2-3 pinnately compound leaves, the rosettes have long petioles, the lower part widens to surround the stem, and the upper part becomes completely a leaf sheath. The lobes are egg-shaped or oval-shaped, have pointed ends, have sharp teeth like thorns, and have some hairs on the surface veins. The flowers bloom in red and white in August and grow in compound umbels, with about 20 small peduncles, 3.8 cm long, without involucre, and with many lanceolate inflorescences, which are linear and much longer than the peduncles. The flowers are pentapodous, have fine protrusions on the ovary, and the fruits are oval-shaped and the ribs of the branches are very thin and evenly developed in the shape of wide wings. In the present invention, the stem of the alpine body may be used.

The Emilia coccinea is a perennial herb of the dicotyledonous plant Campanula Asteraceae, is native to India, and is cultivated as an ornamental plant. The leaves are alternate, long egg-shaped, have dull sawtooth edges, have no petioles, and look like they are powdered. The flowers bloom in an orange-red color from June to October, and a capitate flower (a flower made up of many small flowers without peduncles blooming at the end of a flower stalk, forming a head) hangs at the end of a thin flower stem. The capitol flower is composed of tubular flowers, and the corolla of the tubular flower is divided into five parts. The fruit is an achene. It is sown in spring and has strong properties. Cacalia is derived from the old genus name Cacalia, and is similar to the fireweed.

The fine leaf body (Angelica czernaevia (Fisch. et Meyer) Kitagawa.) is a perennial herb of the dicotyledonous Umbrella family Umbrella and has a height of about 1 m. The leaves grow alternately and are shaped like large triangles, splitting two or three times into feather shapes. About 10 to 30 very small white flowers, about 3 mm in diameter, gather together to form a small umbrella, and about 10 more gather together to form a large umbrella-shaped inflorescence. One flower consists of 5 petals. The fruits that appear after the flowers wither have holes through which oil seeps, making them shiny. White flowers bloom in compound inflorescences in July and August, and the fruit ripens in a ball shape in September and October. Distributed in Gangwon, Gyeonggi, Jeju, etc.

Preferably, the composition for preventing or improving oral diseases of the present invention further includes alpine body extract, Cacalia extract, and fine leaf body extract in the above-mentioned mountain bonech extract, thereby improving oral disease more than a composition containing only the mountain bonech extract. It can show prevention, improvement or treatment effects.

More preferably, it may include 10 to 30 parts by weight of Gosanjeonbae body extract, 10 to 30 parts by weight of Cacalia extract, and 10 to 30 parts by weight of fine leaf body extract, based on 100 parts by weight of the mountain bonech extract.

When used as a complex extract within the above weight part range, a synergistic effect of critical significance is expressed due to the synergistic effect due to the interaction of each extract, and by including it as a complex extract, compared to a composition containing only the mountain golch extract, Comprehensive preference, including taste and aroma, can be improved. On the other hand, if it is outside the above weight part range, the synergistic effect may decrease sharply or may not increase significantly.

The extract is extracted using an extraction solvent selected from the group consisting of water, C ₁ to C ₆ lower alcohols, and mixtures thereof.

The method of preparing the extract may be a conventional extraction method in the art, such as ultrasonic extraction, leaching, and reflux extraction. Specifically, it may be an extract obtained by extracting a natural product from which foreign substances have been removed by washing and drying with water, alcohol having 1 to 6 carbon atoms, or a mixed solvent thereof, and may be an extract obtained by sequentially applying the solvents to the sample.

The ultrasonic extraction method proceeds at 30 to 50°C for 0.5 to 2.5 hours, and the extraction solvent is water or 50 to 100% alcohol with 1 to 6 carbon atoms. Specifically, extraction is performed at 40 to 50°C for 1 to 2.5 hours, and the extraction solvent is water or 70 to 80% alcohol with 1 to 6 carbon atoms.

The leaching method is carried out at 15 to 30°C for 24 to 72 hours, and water or 50 to 100% alcohol with 1 to 6 carbon atoms is used as an extraction solvent. More specifically, it is carried out at 20 to 25°C for 30 to 54 hours, and the extraction solvent is water or 70 to 80% alcohol with 1 to 6 carbon atoms.

The reflux extraction method is based on 100 mL of water and alcohol with 1 to 6 carbon atoms, 10 to 30 g of pulverized natural product, reflux time of 1 to 3 hours, and 50 to 100% of alcohol or water with 1 to 6 carbon atoms. More specifically, based on 100 mL of alcohol with 1 to 6 carbon atoms or 100 mL of water, 10 to 20 g of pulverized natural product, 1 to 2 hours of reflux time, and 70 to 90% of alcohol or water with 1 to 4 carbon atoms.

The extraction solvent can be used in an amount of 2 to 50 times, more specifically, 2 to 20 times the weight of the sample. For extraction, the sample may be left for 1 to 72 hours, more specifically, 24 to 48 hours for leaching in the extraction solvent.

After extraction, the extract can be fractionated by sequentially applying a new fractionation solvent. The fractionating solvent used during fractionation is at least one selected from the group consisting of water, hexane, butanol, ethyl acetic acid, ethyl acetate, methylene chloride, and mixtures thereof, and is preferably ethyl acetate or methylene chloride.

After obtaining the extract or fraction, additional methods such as concentration or freeze-drying can be used.

A food composition for preventing or improving oral diseases according to another embodiment of the present invention includes the composition.

At this time, the amount of the extract in the food or beverage can be added at about 0.01 to 15% by weight of the total weight of the food, and the health drink composition can be added at a rate of about 0.01 to 10g based on 100 ml, but is not limited thereto. .

When the food composition of the present invention is a beverage composition, other than containing the extract as an essential ingredient in the ratio indicated, there are no particular restrictions on other ingredients, and various flavoring agents or natural carbohydrates may be contained as additional ingredients like ordinary beverages. You can. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose, etc.; Disaccharides such as maltose, sucrose, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (thaumatin, stevia extract (e.g. rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used, but are not limited to these. The ratio of the natural carbohydrate may generally range from about 1 to 20 g per 100 ml of the composition of the present invention, but may not be limited thereto.

In addition to the above, the composition of the present invention contains various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavors, colorants and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its It may contain salt, organic acid, protective colloidal thickener, Ph adjuster, stabilizer, preservative, glycerin, alcohol, carbonating agent used in carbonated beverages, etc., but may not be limited thereto.

In addition, the composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks, and these ingredients can be used independently or in combination. The proportion of these additives is not critical, but may be selected in the range of about 0.1 to about 20 parts by weight per 100 parts by weight of the composition of the present invention, but is not limited thereto.

In addition, functional food can be manufactured including the above food composition, and the functional food referred to in the present invention is made of a specific ingredient as a raw material for the purpose of health supplement, or extracts, concentrates, purifies, mixes, etc. a specific ingredient contained in the food raw material. Foods manufactured and processed by methods include health supplements, and are designed and processed to fully exert the bioregulatory functions of food ingredients, such as biodefense, regulation of biorhythm, and disease prevention and recovery, on the living body. It is a food that has functions related to disease prevention and disease recovery, etc.

A quasi-drug composition for preventing or improving oral diseases according to another embodiment of the present invention includes the composition.

The ingredients included in the quasi-drug composition of the present invention are active ingredients and may include ingredients commonly used in oral quasi-drug compositions in addition to the above-mentioned active ingredients, such as abrasives, wetting agents, binders, foaming agents, sweeteners, preservatives, medicinal ingredients, and flavors. It may include agents, pigments, solvents, brighteners, solubilizers, or pH adjusters.

In addition, the quasi-drug composition for preventing or improving oral diseases may be manufactured in any formulation commonly manufactured in the art, but preferably the quasi-drug composition is toothpaste, mouthwash, mouthwash, gum, candy, oral spray, It is one or more formulations selected from the group consisting of oral ointment, oral varnish, oral rinse, and gum massage cream.

A pharmaceutical composition for preventing or treating oral diseases according to another embodiment of the present invention includes the composition.

The pharmaceutical composition may further include one selected from the group consisting of pharmaceutically acceptable carriers, excipients, and diluents. Specifically, the pharmaceutical composition may be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external preparations, suppositories, and sterile injection solutions, respectively, according to conventional methods. You can.

In the present invention, carriers, excipients, and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, and calcium phosphate. , calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations include the extract and its fractions with at least one excipient such as starch, calcium carbonate, It is prepared by mixing sucrose, lactose, and gelatin. In addition to simple excipients, lubricants such as magnesium styrate and talc are also used. Liquid preparations for oral use include suspensions, oral solutions, emulsions, and syrups, and may contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives in addition to the commonly used simple diluents such as water and liquid paraffin. there is. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurin, glycerogenatin, etc. can be used.

The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount, and the term "pharmaceutically effective amount" in the present invention refers to treating or preventing a disease with a reasonable benefit/risk ratio applicable to medical treatment or prevention. It means a sufficient amount, and the effective dose level is determined by the severity of the disease, the activity of the drug, the patient's age, weight, health, gender, the patient's sensitivity to the drug, the administration time, administration route, and excretion rate of the composition of the present invention used. It may be determined depending on factors including the duration of treatment, drugs used in combination or concurrently with the composition of the present invention used, and other factors well known in the medical field. The pharmaceutical composition of the present invention can be administered alone or in combination with a known immunotherapeutic agent. It is important to consider all of the above factors and administer the amount that will achieve the maximum effect with the minimum amount without side effects.

The composition of the present invention can provide a composition based on natural extracts that can prevent, improve, or treat oral diseases, including periodontal disease and dry mouth, by including mountain bone odor extract as an active ingredient.

In addition, the composition of the present invention can be provided as a food composition, quasi-drug composition, or pharmaceutical composition, thereby providing a composition that has no side effects, shows excellent oral disease prevention, improvement, or treatment effects, and has excellent palatability.

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement it. However, the present invention may be implemented in many different forms and is not limited to the embodiments described herein.

[Preparation Example 1: Preparation of natural extract]

1. Preparation of mountain bone extract

After washing the mountain bone with water, it was completely dried naturally. The dried mountain golchwi was pulverized in a blender, leached at room temperature for 36 hours using 80% ethanol, and then the sample was filtered to prepare mountain golchwi extract (SE).

2. Preparation of other extracts

Gosanjeonbu body extract (CE), Cacalia extract (EE), and fine leaf body extract (AE) were prepared in the same manner as the mountain golchwi extract (SE).

3. Preparation of complex extract

A composite extract was prepared by mixing Gosanjeonbae body extract (CE), Cacalia extract (EE), and Aleaf body extract (AE) within the weight range as shown in Table 1 in the same manner as the above-mentioned mountain golchwi extract (SE).

MX1 MX2 MX3 MX4 MX5 MX6 MX7 MX8 MX9 S.E. 100 100 100 100 100 100 100 100 100 C.E. - 20 - - One 10 20 30 40 EE - - 20 - One 10 20 30 40 A.E. - - - 20 One 10 20 30 40

(Unit: parts by weight)

[Experimental Example 1: Measurement of periodontal disease (gingivitis and periodontitis) prevention or improvement activity of mountain bone extract]

1. Experimental method

In order to evaluate the effect of ginseng extract (SE) on improving gingivitis and periodontitis, the cervical ligation rat periodontal disease (EPD), which is currently used as a representative model for improving gingivitis and periodontitis, was evaluated using periodontal disease (EPD). That is, starting 24 hours after tooth neck ligation, mountain snail extract (SE) was dissolved in sterile distilled water and administered orally at a dose of 5 ml/kg (200 mg/kg) once daily for 10 days, and interleukin (IL) in the gingival tissue was administered. )-1β and periodontal bone mass changes were observed along with histopathological changes. At this time, each group was compared and evaluated with the oral administration group of 5 mg/kg indomethacin (IND), an anti-inflammatory agent of the non-steroid antiinflammatory drugs (NSAIDs) class.

Experimental material composition and administration

Sangolchwi extract (SE) was dissolved in sterile distilled water at a concentration of 40 mg/ml, and administered orally at a dose of 5 ml/kg (200 mg/kg) once daily for 10 days starting 24 hours after tooth neck ligation. IND (Anti-inflammatory agent) was dissolved in sterile distilled water at a concentration of 1 mg/ml and administered orally at a dose of 5 ml/kg (5 mg/kg) once daily for 10 days starting 24 hours after tooth neck ligation. In the normal medium control group and the EPD (periodontal disease) control group, in order to apply the same administration stress, only sterilized distilled water, the medium, was administered orally at the same dose and frequency instead of Sanggolchwi extract (SE).

Causes periodontal disease

The experimental animals were acclimatized to the laboratory environment for 10 days and then administered 3% isoflurane (Hana Pharm. Co. ., Hwasung, Korea) and 70% N ₂ O and 28.5% O ₂ mixed gas, followed by ligation using 3-0 nylon suture on the tooth neck of the left incisor to induce periodontitis and gingival disease. . Meanwhile, in the normal medium control group, only the cervical part of the incisor was checked and not ligated.

How to check weight gain

To measure weight gain, body weight changes were measured using an electronic scale during the experiment. 1 day after tooth ligation, body weight is measured on the first day of sample administration, and 10 days later, body weight is measured on the final sample administration day to determine body weight gain. (Weight gain = body weight on the day of sacrifice - body weight at the start of sample administration (24 hours after ligation) after))

Confirmation of changes in interleukin (IL)-1β and TNF-α in gingival tissue

Gingival tissue EPDed for 11 days was homogenized and measured using an ELISA kit (IL-1β rat ELISA kit, Abcam, Cambridge, UK). The test method was conducted according to the manufacturer's method, and 100uL of the homogenized sample and standard were added to each well and incubated in an incubator at 37°C for 2 hours. After incubation, the supernatant is removed, 100uL of 1×biotin-labeled antibody is added to each well, and cultured in an incubator at 37°C for 1 hour. Remove the supernatant from each well, wash three times, add 100uL of 1×horseradish peroxidase-conjugated avidin, and incubate at 37°C for one hour. Add 90uL of 3,3',5,5'-Tetramethylbenzidine to each well and incubate at 37°C for 15 to 30 minutes. After adding 50uL of stop solution to each well, measure the absorbance at a wavelength of 450nm in a microplate reader (Tecan, Mannedofr, Switzerland) and calculate the result.

How to check MDA content

To measure MDA, an indicator of lipid peroxidation, gingival tissue in contact with the ligated area of the tooth is removed, placed in 50mM TrisHCl, 0.1mM EGTA, 1mM phenylmethylsulfonyl fluoride (pH 7.4) buffer, and homogenized using a homogenizer. To 100 ul of homogenized gingival tissue, 200 ul of reaction mixture (8.1% (w/v) sodium dodecyl sulfate, 1500 ul of 20% (v/v) acetic acid, 1500 ul of 0.8% (w/v) thiobarbituric acid, Add 700 ul DW). After reacting at 95°C for 1 hour, centrifuge at 3000 × g for 10 minutes and measure the supernatant at 650nm using a UV/VIS spectrophotometer.

How to measure the number of osteoclasts

The number of osteoclasts was assessed by counting the number of TRAP-positive multinucleated cells through TRAP staining. TRAP staining was performed using the TRAP staining kit (Sigma-Aldrich, St. Louis, MO, USA) by following the staining process described in the kit. The slides that had gone through the deparaffinization and hydration process were immersed in a fixative solution (25 ml of citrate solution, 65 ml of acetone, 8 ml of 37% formaldehyde) for 30 seconds and then washed in running water for 10 minutes. A mixture of 45 ml of 37℃ distilled water, 0.5 ml of fast garnet GBC solution, 0.5 ml of sodium nitrite solution, 0.5 ml of naphthol AS-BI, 2 ml of acetate solution, and 1 ml of tartrate solution was dropped on a slide glass and left on average for about 16 hours. The reaction was performed in a 37°C humid chamber. Afterwards, it was washed with 100% alcohol, stained with methyl green for 1 hour for counterstaining, and sealed. Using an optical microscope, the number of TRAP-positive multinucleated osteoclasts (three or more nuclei) formed along the surface of the alveolar bone was measured.

Confirmation of changes in periodontal bone mass

The amount of periodontal bone loss was measured by Crawford et al. [1987]. It was measured using this method, and after 10 days of sample administration (11 days after EPD), the rat was sacrificed and the teeth and gums were lifted out as much as possible. The area is calculated by paralleling the tip of the gum between the two teeth on which EPD was performed and the tip of the incisor, that is, the lowest part of the tooth protruding from the gum, and expressed in mm/rats.

Method for measuring changes in aerobic viable bacteria count

To measure the number of aerobic bacteria, the ligated left incisor is removed, the periodontal tissue in contact with the ligature is removed, and placed in 0.3 ml of brain heart infusion broth (BHI, Becton, Dicknson and company, USA). After homogenizing the tissue, it was diluted at a ratio of 1:100 and 1:1000, inoculated on blood agar, and cultured at 37°C for 48 hours under 5% CO ₂ conditions. The number of colonies was measured and the number of viable cells was calculated.

Number of viable bacteria = number of colonies × 10 ⁵ CFU/g tissues

2. Experimental results

Changes in body weight in periodontal disease induction model

In the case of the EPD control group, a significant (p<0.05) decrease in body weight compared to the normal medium control group began to be recognized 7 days after ligation (6 days after starting administration), and the amount of weight gain during the 10-day administration period was also normal medium. There was a significant (p<0.01) decrease compared to the control group. Meanwhile, in the group administered with extract (SE), a significant (p<0.01 or p<0.05) increase in body weight was recognized 4 days after the start of administration compared to the EPD control group, confirming the increase in body weight gained by extract (SE). .

Effect of improving gingivitis and periodontitis through confirmation of changes in IL-1β and TNF-α content in gingival tissue in periodontal disease-induced model

Referring to Table 2 below, in the case of the EPD control group, a significant (p<0.01) increase in the content of IL-1β and TNF-α in the gingival tissue was recognized compared to the normal medium control group, but 200 mg/mg/kg of mountain snail extract (SE) was recognized. In the kg administration group, a significant (p<0.01) decrease in IL-1β and TNF-α content in gingival tissue was recognized compared to the EPD control group.

division IL-1β content (pg/mL) TNF-α content (pg/mL) Intact (untreated group, control) 17.24 201.01 E.P.D. 78.67 884.92 IND (5mg/kg) 28.43 327.69 Sangolchwi extract (SE, 200mg/kg) 25.11 296.21

(Unit: pg/mL)

Effect of improving gingivitis and periodontitis through antioxidants by confirming changes in MDA content in gingival tissue in a periodontal disease-induced model

Referring to Table 3 below, in the case of the EPD control group, a significant (p<0.01) increase in MDA content in the gingival tissue was recognized compared to the normal medium control group, but in the group administered 200 mg/kg of sage extract (SE), the EPD control group A significant (p<0.01) decrease in MDA content was recognized.

division MDA contents (μM/mg of tissue) Intact (untreated group, control) 1.72 E.P.D. 9.81 IND (5mg/kg) 5.98 Sangolchwi extract (SE, 200mg/kg) 5.04

(Unit: μM/mg of tissue)

Effect of improving gingivitis and periodontitis through measuring the number of osteoclast cells in periodontal bone in a periodontal disease-induced model

Referring to Table 4 below, the number of osteoclasts in the EPD control group showed a change of 675.65% compared to the normal medium control group, but in the IND and Sangolchwi extract (SE) groups, the number changed by -48.28% and -66.05, respectively, compared to the EPD control group. % change was indicated.

division Osteoclast cells (cells/mm) Intact (untreated group, control) 4.23 E.P.D. 32.81 IND (5mg/kg) 16.97 Sangolchwi extract (SE, 200mg/kg) 11.14

(Unit: cells/mm)

Effect of improving gingivitis and periodontitis through measuring changes in periodontal bone mass in a periodontal disease induction model

Referring to Table 5 below, in the case of the EPD control group, a significant (p<0.01) decrease in periodontal bone mass was recognized compared to the normal medium control group, but in the group administered 200 mg/kg of mountain snail extract (SE), there was a significant decrease compared to the EPD control group. (p<0.01) An increase in periodontal bone mass was recognized.

division Alveolar bone loss scores (mm) Intact (untreated group, control) 0.92 E.P.D. 2.47 IND (5mg/kg) 1.52 Sangolchwi extract (SE, 200mg/kg) 1.34

(Unit: mm)

Effect of improving gingivitis and periodontitis by antibacterial agents by measuring changes in total aerobic bacteria count in the oral buccal area in a periodontal disease-induced model

Referring to Table 6 below, in the case of the EPD control group, a significant (p<0.01) increase in the total number of aerobic viable bacteria in the oral cavity was recognized compared to the normal medium control group, but the IND 5 mg/kg administered group showed a similar number of viable bacteria as the EPD control group. In addition, a significant (p<0.01) decrease in the number of live bacteria in the oral cavity was recognized in the group administered with mountain snail extract (SE) compared to the EPD control group.

division Bad bacteria numbers
(Log ^CFU Intact (untreated group, control) 0.85 E.P.D. 6.97 IND (5mg/kg) 6.84 Sangolchwi extract (SE, 200mg/kg) 2.02

(Unit: Log ^CFU

[Experimental Example 2: Measurement of dry mouth prevention or improvement activity of mountain bone extract]

Saliva secretion function test in salivary gland cells (in vitro)

To confirm damage to salivary gland cells caused by ROS, which is one of the main causes of dry mouth, the production of ROS was induced under high blood sugar conditions (30mM high glucose) and the activity of mountain snail extract (SE) was verified. A253 cells (American Type Culture Collection, Manassas, VA, USA), human submandibular duct cells, were cultured using Complete Growth Medium (American Type Culture Collection, Manassas, VA, USA). After growing ² treated. Afterwards, they were stained with DCF-DA (Invitrogen Corp., CA, USA) and MitoSOX (Invitrogen Corp.), respectively, and then incubated for 1 hour. Afterwards, the amount of ROS generated in the cytoplasm and mitochondria was measured by measuring fluorescence in a fluorescence microplate reader, and the results are shown in Table 7 below.

division DCFH fluorescence (%) MitoSox fluorescence (%) Control 100.00 100.00 HG (30mM) 169.24 132.76 Sangolchwi extract (SE, 10ug/ml) 122.18 116.48 Sangolchwi extract (SE, 50ug/ml) 84.78 107.61 Sangolchwi extract (SE, 100ug/ml) 61.56 103.14

(unit : %)

Referring to Table 7 above, as a result of confirming the amount of ROS generated in the cytoplasm using DCFH dye, the production of ROS increased by about 1.7 times under high glucose conditions, and the amount of ROS produced in the cytoplasm was increased by about 1.7 times, and the amount of ROS produced in the cytoplasm was increased by about 1.7 times when the extract (SE) was used at 10 to 100 ug/ml. As a result of treatment at a concentration of , the efficacy of suppressing the production of ROS was confirmed in a concentration-dependent manner. In addition, as a result of confirming the amount of ROS generated in mitochondria using MitoSox dye, similar to the previous results, it was confirmed that the amount of ROS generated in high glucose was reduced in a concentration-dependent manner by treatment with mountain snail extract (SE). .

Analysis of expression levels of salivary digestive enzyme amylase and water pump Aquaporin-5

To verify the effectiveness of mountain golchwi extract (SE) in promoting saliva secretion from salivary gland cells, the expression levels of the salivary digestive enzyme amylase and water pump Aquaporin-5 were analyzed. A253 cells were grown at ² Afterwards, proteins were extracted and western blot was performed. After measuring the protein concentration using a BCA kit (Sigma-Alderich Co. LLC), the same amount of protein was electrophoresed on an SDS-PAGE gel and transferred to a Hybond-ECL nitrocellulose membrane (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA).

Afterwards, the membrane was blocked with 0.1% skim milk for 1 hour, reacted with primary antibody for 1 hour, then reacted with HRP-conjugated secondary antibody (Thermo Fisher Scientific Inc.) for 1 hour, and SuperSignal West Pico ECL Proteins were detected in solution (Thermo Fisher Scientific Inc.) and detected with a Fuji LAS-3000 system (Fujifilm, Tokyo, Japan). The primary antibodies used in this experiment were mouse anti-amylase antibody (Santa Cruz Biotechnology, CA, USA), rabbit anti-AQP5 antibody (Santa Cruz Biotechnology), and β-actun (Sigma-Alderich Co. LLC). The experimental results are shown in Table 8 below.

division Relative expression levels of amylase(AU) Relative expression levels of AQP5(AU) Control 1.02 1.01 HG (30mM) 0.45 0.34 Sangolchwi extract (SE, 10ug/ml) 1.59 1.85 Sangolchwi extract (SE, 50ug/ml) 2.14 2.94 Sangolchwi extract (SE, 100ug/ml) 2.36 3.31

(Unit: AU)

Referring to Table 8 above, when treated with high glucose (HG), the expression level of amylase, a digestive enzyme, in salivary gland cells decreases, and the expression level of aquaporin-5 (AQP5), an important pump that secretes saliva in salivary cells, significantly decreases. It decreases. However, it was confirmed that when Sangolchwi extract (SE) was treated at a concentration of 10 to 100 ug/ml, the expression level of these proteins increased in a concentration-dependent manner.

Evaluation of the efficacy of promoting saliva secretion in diabetic rats (in vivo)

Six-week-old male SD rats (Samtaco, Korea) were used after acclimatization for one week. Feed and drinking water were provided ad libitum. Diabetes was induced with STZ (60 mg/kg, ip), and a week later, only those with blood sugar levels above 350 mg/dl were selected and used in the experiment. The groups were separated and the test drugs were administered as follows. (1) Normal group (control), (2) Diabetes-induced group (Diabetes), (3) Sanggolchwi extract (SE) 100 mg/kg administered group, (4) Sanggolchwi extract (SE) 250 mg/kg administered group. The test drug was administered orally once a day for 4 weeks. An autopsy was performed 4 weeks after drug administration for each group. To measure saliva secretion, pilocarpine9 (0.6 mg/kg) was intraperitoneally injected into rats to induce salivation. Afterwards, a cotton ball whose weight was previously measured was placed in the oral cavity and left for 1 minute to absorb the secreted saliva. After 1 minute, the saliva is absorbed and the wet cotton ball is recovered, its weight is measured, and the saliva is recovered by centrifugation at 10,000 rpm to quantify the amount of saliva. Salivary secretion was measured four times, once a week for four weeks, and the results are shown in Table 9 below.

division Salivary flow rate(μL/min) 1 week 2 weeks 3 weeks 4 weeks Control 98.18 97.28 98.54 99.25 Diabetes 47.25 40.84 38.17 11.48 Sangolchwi extract (SE, 100mg/kg) 51.91 54.37 56.44 58.54 Sangolchwi extract (SE, 250mg/kg) 58.49 60.21 63.48 66.87

(Unit: μL/min)

Referring to Table 9 above, in mice induced with diabetes, the amount of saliva secretion decreased by about half after 1 week, and over the next 4 weeks, the amount of saliva secretion gradually decreased, reaching a state where almost no saliva was secreted after 4 weeks. However, although the amount of saliva secreted in mice administered mountain snail extract (SE) decreased compared to normal mice, no further decrease in saliva volume was observed in both the 1000 mg/kg and 250 mg/kg administration groups. Although it was a small amount, a small increase in saliva secretion was observed after 4 weeks of administration.

[Experimental Example 3: Measurement of oral disease prevention or improvement activity of complex extract]

The experimental evaluation results of the remaining complex extracts (MX2 to MX9) were evaluated using the same method as the experimental method showing the activity of preventing or improving periodontal disease and dry mouth of the mountain bone extract (SE) shown in Experimental Examples 1 and 2 above. The experimental results of MX1) were compared with the exponent 3 and are comprehensively shown in Table 10 below.

The higher the number, the better the activity in preventing, treating or improving periodontal disease and dry mouth, and the experimental results were expressed as an index of 1 to 10.

MX1 MX2 MX3 MX4 MX5 MX6 MX7 MX8 MX9 Decreased IL-1β and TNF-α content in gingival tissue 3 3 4 4 5 8 8 8 6 Reduced MDA content in gingival tissue 3 4 4 4 5 8 8 9 6 Reduction of osteoclasts in periodontal bone 3 3 3 4 5 8 9 9 7 Increased periodontal bone mass 3 3 4 3 6 8 8 8 6 Decrease in total aerobic bacteria count in the oral isthmus 3 4 3 3 5 8 9 9 7 Increased saliva production 3 4 3 4 6 8 9 9 6

(Unit: index)

Referring to Table 10 above, experiments related to periodontal disease include a decrease in IL-1β and TNF-α content in gingival tissue, a decrease in MDA content in gingival tissue, a decrease in osteoclasts in periodontal bone, an increase in periodontal bone mass, and the total number of aerobic bacteria in the oral isthmus. In terms of reduction, it can be seen that there is a slight improvement in the case of MX2 to MX4, which each contain more natural extracts, compared to MX1, which contains only the mountain bone extract, and in the case of MX5 to MX9, which are compositions that mix natural extracts, the activity increases due to the mixing action. It can be confirmed that this results in improved results. Furthermore, in the case of MX6 to MX8 containing a preferable weight part of natural extract, the activity is greatly improved, and for 100 parts by weight of mountain golchwi extract (SE), 10 to 30 parts by weight of high mountain body extract (CE) and Cacalia extract. It can be seen that by including 10 to 30 parts by weight of (EE) and 10 to 30 parts by weight of leaf body extract (AE), the prevention, improvement or treatment effect of periodontal disease can be excellent.

Meanwhile, in an experiment for dry mouth, saliva secretion was increased when more natural extracts were included compared to MX1 treated with only mountain bone extract, showing that saliva secretion can be more active by including natural extracts. It can be seen that treatment with MX5 to MX9, which is a mixture of all three natural extracts, shows an activity in improving dry mouth, rather than using them alone. In addition, as in the periodontal disease-related experiment, for 100 parts by weight of the mountain bone extract, 10 to 30 parts by weight of the alpine body extract (CE), 10 to 30 parts by weight of the Cacalia extract (EE), and 10 to 10 to 30 parts by weight of the leaf body extract (AE) In the case of 30 parts by weight of MX6 to MX8, the activity was greatly improved, and it was confirmed that the prevention, improvement, or treatment activity for dry mouth could be excellent by including them in a preferred weight part rather than simply mixing them.

[Experimental Example 4: Evaluation of preference for tea drinks]

The tea beverages containing the above MX1 to MX9 were sampled by 30 male and female testers in their 20s to 40s, and were then evaluated for aroma and taste, and preference was evaluated on a scale of 1 to 10. The results were compiled and averaged and shown in Table 11 below. The higher the index below, the better the preference, and each index is expressed by applying rounding to the average value.

MX1 MX2 MX3 MX4 MX5 MX6 MX7 MX8 MX9 taste 2 3 3 4 6 8 9 9 7 incense 2 2 4 4 6 8 8 9 6 Synthesis
preference 2 3 4
4 6 8 9 9 7

(Unit: index)

Referring to Table 11, compared to the case of MX1 containing only the mountain bone extract according to the present invention, MX2 to MX4 further include the natural extracts Gosanbu body extract (CE), Cacalia extract (EE), and Aleaf body extract (AE). In the case of , it can be seen that preference for taste and aroma improves.

In addition, it can be confirmed that MX5 to MX9, which contain all of the above-mentioned alpine body extract (CE), Cacalia extract (EE), and fine leaf body extract (AE), show more improved preference than that of MX5 to MX9, but for 100 parts by weight of mountain golchwi extract It can be seen that the overall preference is very good when it contains 10 to 30 parts by weight of high-acid body extract (CE), 10 to 30 parts by weight of Cacalia extract (EE), and 10 to 30 parts by weight of leaf body extract (AE).

Therefore, in the case of the above mixed formulation, it can be seen that the preference for mountain golchwi extract (MX1, SE) can be improved based on natural extracts. As a result, there are no problems such as side effects due to long-term use, It can be confirmed that it is possible to provide a composition with excellent functionality and preference as it not only has excellent functionality for oral diseases including periodontal disease and dry mouth, but also has high palatability.

Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements made by those skilled in the art using the basic concept of the present invention defined in the following claims are also possible. falls within the scope of rights.

Claims (7)

Contains mountain bone extract
Composition for preventing or improving oral diseases. According to clause 1,
The oral disease is selected from the group consisting of periodontal disease, dry mouth, dental caries, toothache, dry teeth, and bad breath.
Composition for preventing or improving oral diseases. According to clause 1,
The extract is extracted using an extraction solvent selected from the group consisting of water, C ₁ to C ₆ lower alcohols, and mixtures thereof.
Composition for preventing or improving oral diseases. Comprising the composition according to any one of claims 1 to 3
Food composition for preventing or improving oral diseases. Comprising the composition according to any one of claims 1 to 3
Quasi-drug composition for preventing or improving oral diseases. According to clause 5,
The quasi-drug composition is one or more formulations selected from the group consisting of toothpaste, mouthwash, mouthwash, gum, candy, oral spray, oral ointment, oral varnish, oral rinse, and gum massage cream.
Quasi-drug composition for preventing or improving oral diseases. Comprising the composition according to any one of claims 1 to 3
Pharmaceutical composition for preventing or treating oral diseases.